Marketplace All-in-One Tariffs won't force a major Swiss pharma company to move production
Aug 8, 2025
Pharmaceutical giant Sandoz insists that upcoming tariffs won't drive them to relocate their manufacturing to the U.S., discussing the complexities of medication costs. Meanwhile, major developments arise as Intel's CEO faces pressure amidst geopolitical tensions. The podcast also dives into the Congolese government's striking partnership with Barcelona FC, highlighting efforts to boost tourism through soccer sponsorship while grappling with pressing social issues. These discussions reveal the intricate balance between business strategies and national priorities.
AI Snips
Chapters
Transcript
Episode notes
Tariffs Alone Won't Reshore Pharma Production
- Richard Sayner says tariffs alone won't justify building US manufacturing sites.
- He cites high costs and long timelines that tariffs can't quickly offset.
Sandoz Focuses On Generics And Biosimilars
- Felicity Hanna explains Sandoz makes generics and biosimilars, not new drugs.
- These copycat medicines sell at a fraction of brand-name prices after patents expire.
Offshoring Driven By Price Pressures
- Richard Sayner highlights that low prices pushed manufacturing offshore to India and China.
- He links a race-to-the-bottom on costs to lost US manufacturing capacity.